ESSA Pharma Inc. (EPIX): Price and Financial Metrics


ESSA Pharma Inc. (EPIX): $2.82

-0.33 (-10.48%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

EPIX Stock Price Chart Interactive Chart >

Price chart for EPIX

EPIX Price/Volume Stats

Current price $2.82 52-week high $29.70
Prev. close $3.15 52-week low $2.82
Day low $2.82 Volume 158,100
Day high $3.11 Avg. volume 232,084
50-day MA $5.10 Dividend yield N/A
200-day MA $8.50 Market Cap 124.13M

ESSA Pharma Inc. (EPIX) Company Bio


ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor. The company was founded in 2009 and is based in Vancouver, Canada.


EPIX Latest News Stream


Event/Time News Detail
Loading, please wait...

EPIX Latest Social Stream


Loading social stream, please wait...

View Full EPIX Social Stream

Latest EPIX News From Around the Web

Below are the latest news stories about ESSA Pharma Inc that investors may wish to consider to help them evaluate EPIX as an investment opportunity.

EPIX: First Patient Dosed in Combination Trial of EPI-7386 and Enzalutamide…

By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Dosing Underway for Combination Trial of EPI-7386 and Enzalutamide On January 19, 2022, ESSA Pharma, Inc. (NASDAQ:EPIX) announced that the first patient has been dosed in the Phase 1/2 clinical trial of EPI-7386 and enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) who have not

Yahoo | February 4, 2022

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2021

ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal first quarter ended December 31, 2021. All references to "$" in this release refer to United States dollars, unless otherwise indicated.

Yahoo | February 3, 2022

ESSA Pharma Announces First Patient Dosed in a Phase 1/2 Clinical Trial of EPI-7386 in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

ESSA Pharma Inc. (NASDAQ: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the first patient dosed in the Company-sponsored Phase 1/2 study to evaluate the safety, tolerability and preliminary efficacy of ESSA's lead product candidate, EPI-7386, a first-in-class N-terminal domain androgen receptor inhibitor, in combination with Astellas Pharma Inc.'s ("Astellas") and Pfizer Inc.'s

Yahoo | January 19, 2022

Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ...

Cambridge, MA, based Investment company Opaleye Management Inc. (Current Portfolio) buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics Pharmaceuticals Inc, Amicus Therapeutics Inc, Merus NV, sells ESSA Pharma Inc, Seres Therapeutics Inc, CM Life Sciences Inc, Lumos Pharma Inc, Kezar Life Sciences Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Opaleye Management Inc..

Yahoo | December 28, 2021

Penn Series Small Cap Growth Fund Buys Core & Main Inc, Clear Secure Inc, Inotiv Inc, Sells ...

Investment company Penn Series Small Cap Growth Fund (Current Portfolio) buys Core & Main Inc, Clear Secure Inc, Inotiv Inc, Rogers Corp, CarParts.com Inc, sells Guidewire Software Inc, Alarm.com Holdings Inc, Standex International Corp, H.B.

Yahoo | December 11, 2021

Read More 'EPIX' Stories Here

EPIX Price Returns

1-mo -42.09%
3-mo -57.34%
6-mo -80.47%
1-year -90.03%
3-year 20.24%
5-year -73.89%
YTD -80.14%
2021 19.03%
2020 116.91%
2019 161.90%
2018 -52.05%
2017 -90.00%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5315 seconds.